IL84114A - Anti-neoplastic pharmaceutical compositions containing HSG together with an anti-tumor drug - Google Patents

Anti-neoplastic pharmaceutical compositions containing HSG together with an anti-tumor drug

Info

Publication number
IL84114A
IL84114A IL8411487A IL8411487A IL84114A IL 84114 A IL84114 A IL 84114A IL 8411487 A IL8411487 A IL 8411487A IL 8411487 A IL8411487 A IL 8411487A IL 84114 A IL84114 A IL 84114A
Authority
IL
Israel
Prior art keywords
gsh
glutathione
platinum
antitumor
agent
Prior art date
Application number
IL8411487A
Other languages
English (en)
Hebrew (he)
Other versions
IL84114A0 (en
Original Assignee
Boehringer Mannheim Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT21925/86A external-priority patent/IT1197485B/it
Priority claimed from IT8748339A external-priority patent/IT1211748B/it
Application filed by Boehringer Mannheim Italia filed Critical Boehringer Mannheim Italia
Publication of IL84114A0 publication Critical patent/IL84114A0/xx
Publication of IL84114A publication Critical patent/IL84114A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL8411487A 1986-10-07 1987-10-06 Anti-neoplastic pharmaceutical compositions containing HSG together with an anti-tumor drug IL84114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT21925/86A IT1197485B (it) 1986-10-07 1986-10-07 Composizioni farmaceutiche ad attivita' antineoplastica
IT8748339A IT1211748B (it) 1987-09-01 1987-09-01 Composizioni farmaceutiche ad atti vita'antineoplastica

Publications (2)

Publication Number Publication Date
IL84114A0 IL84114A0 (en) 1988-03-31
IL84114A true IL84114A (en) 1994-01-25

Family

ID=26328046

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8411487A IL84114A (en) 1986-10-07 1987-10-06 Anti-neoplastic pharmaceutical compositions containing HSG together with an anti-tumor drug

Country Status (11)

Country Link
US (1) US4871528A (de)
EP (1) EP0265719B1 (de)
KR (1) KR950013762B1 (de)
AU (1) AU605512B2 (de)
CA (1) CA1306693C (de)
DE (1) DE3768419D1 (de)
ES (1) ES2036553T3 (de)
GR (1) GR3001578T3 (de)
HK (1) HK66594A (de)
IL (1) IL84114A (de)
PH (1) PH23232A (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265719B1 (de) * 1986-10-07 1991-03-06 Boehringer Mannheim Italia S.P.A. Pharmazeutische Zusammensetzungen mit antineoplastischer Wirkung
EP0334083B1 (de) * 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
EP0486621A4 (en) * 1989-08-09 1993-03-31 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
IT1238078B (it) * 1990-01-31 1993-07-05 Silvano Spinelli Cis-platino complessi con ammine e sulfinilcarbossilati chelanti
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5378456A (en) * 1993-03-25 1995-01-03 American Cyanamid Company Antitumor mitoxantrone polymeric compositions
US5609867A (en) * 1994-11-01 1997-03-11 American Cyanamid Company Polymeric antitumor agents
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US6197749B1 (en) * 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
GB0011059D0 (en) 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
GB0015446D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
GB0015447D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0016447D0 (en) 2000-07-04 2000-08-23 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
IT1318696B1 (it) 2000-09-15 2003-08-27 Pharmacia & Upjohn Spa Coniugati di glutatione con derivati della distamicina ad attivita'antitumorale.
GB0029004D0 (en) 2000-11-28 2001-01-10 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
US6969592B2 (en) 2001-09-26 2005-11-29 Pharmacia Italia S.P.A. Method for predicting the sensitivity to chemotherapy
ITMI20052449A1 (it) * 2005-12-22 2007-06-23 Cell Therapeutics Europe Srl Nuovi bis-platino complessi ad attivita' antitumorale
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265719B1 (de) * 1986-10-07 1991-03-06 Boehringer Mannheim Italia S.P.A. Pharmazeutische Zusammensetzungen mit antineoplastischer Wirkung

Also Published As

Publication number Publication date
EP0265719A1 (de) 1988-05-04
EP0265719B1 (de) 1991-03-06
AU605512B2 (en) 1991-01-17
KR880004808A (ko) 1988-06-27
DE3768419D1 (de) 1991-04-11
CA1306693C (en) 1992-08-25
GR3001578T3 (en) 1992-11-23
US4871528A (en) 1989-10-03
PH23232A (en) 1989-06-06
AU7939887A (en) 1988-04-14
KR950013762B1 (en) 1995-11-15
HK66594A (en) 1994-07-15
IL84114A0 (en) 1988-03-31
ES2036553T3 (es) 1993-06-01

Similar Documents

Publication Publication Date Title
EP0265719B1 (de) Pharmazeutische Zusammensetzungen mit antineoplastischer Wirkung
Al-Sarraf et al. Platinum Analogs in Recurrent and Advanced Head and Neck Cancer: A Southwest Oncology Group and Wayne State University Study 1, 2, 3
Ozols et al. High dose cisplatin and high dose carboplatin in refractory ovarian cancer
EP1576956A2 (de) Chromium/Biotin Behandlung von Typ-II Diabetes
CA2281807C (en) Method of treating a tumor
CA2297834C (en) Chromium/biotin treatment of type ii diabetes
US5049396A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment
Woodman et al. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943)
US6297245B1 (en) Cisplatin and folic acid administered to treat breast cancer
Valdivieso et al. Phase I clinical study of dihydroxyanthracenedione administered on a 5 day iv schedule
Collier et al. Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma
EP0140958B1 (de) Onkolytische arzneimittelkombinationen
JPS63258414A (ja) 抗腫瘍剤
JPS63246334A (ja) 抗新生物作用を有する薬学的組成物
Gasparini et al. Continuous cisplatin infusion in combination with vincristine and high-dose methotrexate for advanced osteogenic sarcoma
EP0874630B1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
US4006235A (en) Treating CNS lymphoma
Mori et al. Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer
CA2202389A1 (en) Agent for preventing and treating diarrhea
US6265385B1 (en) Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
US20060142239A1 (en) Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine
Hegg et al. A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer
WO1996030024A1 (en) The pharmaceutical composition containing the 1,3,2-oxazaphosphorinane and mesna for the cancer treatment
KR20020026743A (ko) 비소화합물 및 글루타치온 고갈 유도 화합물을 함유하는항암조성물
Elliott et al. Enhanced therapeutic effect of amsalog (CI-921) in combination with cisplatin in vitro and in vivo

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees